Liminal BioSciences Inc.
LMNL · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $372 | $1,166 | $4,532 | $9,199 |
| - Cash | $37,144 | $108,490 | $45,075 | $61,285 |
| + Debt | $1,487 | $60,782 | $73,984 | $47,071 |
| Enterprise Value | -$35,285 | -$46,542 | $33,441 | -$5,015 |
| Revenue | $401 | $643 | $3,317 | $4,904 |
| % Growth | -37.6% | -80.6% | -32.4% | – |
| Gross Profit | $401 | $643 | $1,284 | $2,141 |
| % Margin | 100% | 100% | 38.7% | 43.7% |
| EBITDA | -$31,855 | -$45,213 | -$105,167 | -$200,724 |
| % Margin | -7,943.9% | -7,031.6% | -3,170.5% | -4,093.1% |
| Net Income | -$28,916 | -$45,063 | -$122,137 | -$234,224 |
| % Margin | -7,211% | -7,008.2% | -3,682.2% | -4,776.2% |
| EPS Diluted | -9.32 | -14.94 | -49.97 | -145.82 |
| % Growth | 37.6% | 70.1% | 65.7% | – |
| Operating Cash Flow | -$31,820 | -$99,603 | -$75,917 | -$99,390 |
| Capital Expenditures | -$19 | -$463 | -$2,046 | -$4,444 |
| Free Cash Flow | -$31,839 | -$100,066 | -$77,963 | -$103,834 |